ANNOUNCEMENT NO. 286 9 December 2024 Major shareholder announcement Major shareholder announcement – Invesco Ltd. Pursuant to Section 30…
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of…
Breakthrough Innovation for the Purification of mRNA Therapeutics and VaccinesWALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN),…
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant…
Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San…
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE…
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd.…
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA,…
PRESS RELEASE EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris, France,…
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09,…